GoAI
Get started
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.41

+$0.08 · +1.26%

Aug 21, 4:00 PM ET

ACRS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

25

Expensive

Momentum

71

Gaining

Sentiment

74

Bullish

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Neal S. Walker
Listed since
Oct 6, 2015
Employees
71

Market position

Day range

Current $6.41

52-week range

Current $6.41

Open
$6.36
Previous close
$6.33
Volume
2.21M
1.32× average
Average volume
1.68M
Average daily volume
Market cap
895.24M USD
Beta
0.78
Market reference 1
50-day average
$5.4393
+17.85% above average
200-day average
$4.0229
+59.34% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
351.38M USD
P/E (TTM)
-11.05×
P/B (TTM)
7.34×
P/S (TTM)
108.92×
EV / EBITDA
-5.45×
Earnings yield
-17.58%
Free cash flow yield
-12.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
95.61%
Operating margin
-1050.16%
Net margin
-921.50%
Return on equity
-62.98%
Return on assets
-40.46%
Return on invested capital
-57.70%

Financial health

Debt / equity
0×
Current ratio
5.28×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends228%-344%-915%-1487%Gross margin, FY2021: 30.29%Gross margin, FY2022: 59.80%Gross margin, FY2023: 42.14%Gross margin, FY2024: 85.09%Gross margin, FY2025: 73.28%Operating margin, FY2021: -1327.07%Operating margin, FY2022: -302.01%Operating margin, FY2023: -311.55%Operating margin, FY2024: -758.18%Operating margin, FY2025: -975.91%Net margin, FY2021: -1343.96%Net margin, FY2022: -292.11%Net margin, FY2023: -283.15%Net margin, FY2024: -705.48%Net margin, FY2025: -829.58%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 30.29%. Gross margin FY2022 59.80%. Gross margin FY2023 42.14%. Gross margin FY2024 85.09%. Gross margin FY2025 73.28%. Operating margin FY2021 -1327.07%. Operating margin FY2022 -302.01%. Operating margin FY2023 -311.55%. Operating margin FY2024 -758.18%. Operating margin FY2025 -975.91%. Net margin FY2021 -1343.96%. Net margin FY2022 -292.11%. Net margin FY2023 -283.15%. Net margin FY2024 -705.48%. Net margin FY2025 -829.58%.

Income trends

Revenue

7.83M USD-58.19%

Operating income

−76.38M USD+46.19%

Net income

−64.92M USD+50.84%
Income trends across reported periods48.57M USD−20.71M USD−89.98M USD−159.25M USDRevenue, FY2021: 6.76M USDRevenue, FY2022: 29.75M USDRevenue, FY2023: 31.25M USDRevenue, FY2024: 18.72M USDRevenue, FY2025: 7.83M USDOperating income, FY2021: −89.72M USDOperating income, FY2022: −89.85M USDOperating income, FY2023: −97.36M USDOperating income, FY2024: −141.93M USDOperating income, FY2025: −76.38M USDNet income, FY2021: −90.87M USDNet income, FY2022: −86.91M USDNet income, FY2023: −88.48M USDNet income, FY2024: −132.07M USDNet income, FY2025: −64.92M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 6.76M USD. Revenue FY2022 29.75M USD. Revenue FY2023 31.25M USD. Revenue FY2024 18.72M USD. Revenue FY2025 7.83M USD. Operating income FY2021 −89.72M USD. Operating income FY2022 −89.85M USD. Operating income FY2023 −97.36M USD. Operating income FY2024 −141.93M USD. Operating income FY2025 −76.38M USD. Net income FY2021 −90.87M USD. Net income FY2022 −86.91M USD. Net income FY2023 −88.48M USD. Net income FY2024 −132.07M USD. Net income FY2025 −64.92M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.83M USD18.72M USD31.25M USD29.75M USD6.76M USD
Cost of goods sold2.09M USD2.79M USD18.08M USD11.96M USD4.71M USD
Gross profit5.74M USD15.93M USD13.17M USD17.79M USD2.05M USD
Research and development52.65M USD33.59M USD98.38M USD77.81M USD43.81M USD
Selling, general, and administrative21.97M USD22.2M USD31.1M USD25.13M USD23.62M USD
Operating expenses82.11M USD157.86M USD110.53M USD107.65M USD91.77M USD
Interest income7.64M USD7.95M USD———
Depreciation and amortization454K USD807K USD863K USD797K USD923K USD
Operating income−76.38M USD−141.93M USD−97.36M USD−89.85M USD−89.72M USD
Net income−64.92M USD−132.07M USD−88.48M USD−86.91M USD−90.87M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.53
FY2025
Latest fiscal-year revenue
7.83M USD
FY2025 · -58.19% year over year
Next fiscal-year EPS consensus
-0.668
FY2026 · 8 analysts
Next fiscal-year revenue consensus
5.86M USD
FY2026 · 7 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.21-0.75-1.3-1.85FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend34.28M22.14M10M-2.14MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.75

67.71% upside
Past 12 months12-month forecastHigh $12.00Average $10.75Low $10.00

Rating distribution

16 ratings
Strong buy00%
Buy1381%
Hold319%
Sell00%
Strong sell00%

Recent analyst actions

10 institutions
ScotiabankmaintainSector Outperform
JefferiesupgradeHoldBuy
Leerink PartnersupgradeMarket PerformOutperform

ACRS news

zacks.com

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean…

Read source
globenewswire.com

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today…

Read source
zacks.com

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.

Read source
globenewswire.com

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b…

Read source
zacks.com

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Read source
marketbeat.com

3 Penny Stocks Under $5 Backed by Real Revenue Growth

Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.

Read source

ACRS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ACRS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
22.07M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
19.29M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.55M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
6.08M
Weight
0.04%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
5.59M
Weight
1.00%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
5.18M
Weight
0.05%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
5.04M
Weight
0.08%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.45M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research ACRS

research.disclaimer